Table 1 Cohort clinical characteristics.
From: Spatial proteomics of breast ductal carcinoma in situ reveal distinct regional differences
Characteristic | DCIS with No Recurrence (NR) (n = 35) | DCIS with DCIS Recurrence (DR) (n = 35) | DCIS with Invasive Recurrence (IR) (n = 33) | Total (n = 103) |
|---|---|---|---|---|
Age at diagnosis (years) | 50 (41–72) | 52 (40–73) | 49 (38–72) | 50 (38–73) |
ER status | ||||
Positive | 25 (71.4) | 26 (74.3) | 25 (75.8) | 76 (73.8) |
Negative | 10 (28.6) | 9 (25.7) | 8 (24.2) | 27 (26.2) |
Unknown | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
HER2 status | ||||
Positive | 11 (31.4) | 13 (37.1) | 8 (24.2) | 32 (31.1) |
Negative | 24 (68.6) | 20 (57.1) | 25 (75.8) | 69 (67.0) |
Unknown | 0 (0.0) | 2 (5.7) | 0 (0.0) | 2 (1.9) |
ER|HER2 status | ||||
Positive/Positive | 3 (8.6) | 5 (14.3) | 2 (6.1) | 10 (9.7) |
Negative/Negative | 2 (5.7) | 1 (2.9) | 2 (6.1) | 5 (4.9) |
Positive/Negative | 22 (62.9) | 19 (54.3) | 23 (69.7) | 64 (62.1) |
Negative/Positive | 8 (22.9) | 8 (22.9) | 6 (18.2) | 22 (21.4) |
Unknown | 0 (0.0) | 2 (5.7) | 0 (0.0) | 2 (1.9) |
DCIS grade | ||||
1 | 0 (0.0) | 3 (8.6) | 2 (6.1) | 5 (4.9) |
2 | 15 (42.9) | 13 (37.1) | 13 (39.4) | 41 (39.8) |
3 | 20 (57.1) | 19 (54.3) | 18 (54.5) | 57 (55.3) |
Breast Surgical Procedure | ||||
Lumpectomy | 22 (62.9) | 28 (80.0) | 19 (57.6) | 69 (67.0) |
Mastectomy | 13 (37.1) | 7 (20.0) | 13 (39.4) | 33 (32.0) |
Unknown | 0 (0.0) | 0 (0.0) | 1 (3.0) | 1 (1.0) |
Radiation for DCIS | ||||
Yes | 20 (57.1) | 22 (62.9) | 12 (36.4) | 54 (52.4) |
No | 14 (40.0) | 12 (34.3) | 17 (51.5) | 43 (41.7) |
Unknown | 1 (2.9) | 1 (2.9) | 4 (12.1) | 6 (5.8) |
Endocrine therapy | ||||
Yes | 12 (34.3) | 12 (34.3) | 13 (39.4) | 37 (35.9) |
No | 21 (60.0) | 19 (54.3) | 16 (48.5) | 56 (54.4) |
Unknown | 2 (5.7) | 4 (11.4) | 4 (12.1) | 10 (9.7) |
Time to recurrence (years) | 7.8 | 3.8 | 4.8 |
